Home miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
Article
Licensed
Unlicensed Requires Authentication

miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy

  • Kadriye Akpınar ORCID logo EMAIL logo , Diler Aslan ORCID logo , Semin Melahat Fenkçi ORCID logo and Vildan Caner ORCID logo
Published/Copyright: August 18, 2022
Diagnosis
From the journal Diagnosis Volume 9 Issue 4

Abstract

Objectives

Microribonucleic acids (microRNA/miRNA/miR-) are predicted to be useful in the early diagnosis, monitoring, and treatment of diabetic nephropathy (DN). We aimed to investigate the relationship of DN to miR-21-3p, miR-29a-3p, miR-29b-3p, miR-29c-3p, miR-126-3p, miR-129-1-3p, miR-137, miR-192-5p, miR-212-3p, and miR-320c.

Methods

There were 50 healthy controls and 100 patients with type 2 diabetes mellitus (T2DM). The diabetic patients were divided into three subgroups: normal to mildly increased (A1, n=51), moderately increased (A2, n=25), and severely increased (A3, n=24) albuminuria. The biochemical measurements were analysed using Roche Cobas 8000. The plasma miRNAs were analysed using RT-qPCR based on SYBR green chemistry.

Results

The relative expression of miR-21-3p was significantly lower in the (A3 p=0.005, 6.6-fold decrease) and DN (A1 + A3) (p=0.005, 6.6-fold decrease) groups compared to the controls. The relative expression of miR-192-5p was also significantly lower in the DN group (p=0.027, 2.4-fold decrease) compared to the controls. The area under curve value was 0.726 for miR-21-3p and 0.717 for miR-192-5p for distinguishing the DN group from the controls.

Conclusions

The decreased expressions of miR-21-3p and miR-192-5p are associated with the development of DN and may be potential biomarkers for the early diagnosis of DN.

Keywords: circulating microRNAs; diabetes mellitus; diabetic nephropathy
Corresponding author: Kadriye Akpınar, Department of Medical Biochemistry, School of Medicine, Pamukkale University, Burdur State Hospital, Biochemistry Laboratory, 15030, Denizli, Burdur, Turkey, E-mail:

Acknowledgments

Grant sponsor: Pamukkale University Scientific Research Projects Department (grant number and date: 2017TIPF018, 26/12/2017).

  1. Research funding: This work was supported by the Pamukkale University Scientific Research Projects Department.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by the Research and Ethics Committee of the Medical Faculty of Pamukkale University (approval number: 07; date 16/05/2017).

References

1. World Health Organization. Global report on diabetes. Geneva, Switzerland: World Health Organization; 2016978–88 p.Search in Google Scholar

2. KDIGO CKD Work Group. Kidney Disease: improving Global Outcomes (KDIGO) 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–136.Search in Google Scholar

3. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of Diabetes in Canada. Can J Diabetes 2018;42:1–342.10.1016/S1499-2671(17)31026-2Search in Google Scholar

4. Simpson, K, Wonnacott, A, Fraser, DJ, Bowen, T. MicroRNAs in diabetic nephropathy: from Biomarkers to therapy. Curr Diabetes Rep 2016;16:1–7. https://doi.org/10.1007/s11892-016-0724-8.Search in Google Scholar PubMed PubMed Central

5. Jonas, S, Izaurralde, E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015;16:421–33. https://doi.org/10.1038/nrg3965.Search in Google Scholar PubMed

6. Sohel, MH. Extracellular/circulating MicroRNAs: release mechanisms, functions and challenges. Achiev Life Sci 2016;10:175–86. https://doi.org/10.1016/j.als.2016.11.007.Search in Google Scholar

7. Chiu, RWK, Dennis Lo, YM. Principles of molecular biology. In: Tietz Textb Clin Chem Mol Diagnostics, 5th ed. Philadelphia: W. B. Saunders Co.; 2012:1209–23 pp.10.1016/B978-1-4160-6164-9.00037-8Search in Google Scholar

8. Ghai, V, Baxter, D, Wu, X, Kim, TK, Kuusisto, J, Laakso, M, et al.. Circulating RNAs as predictive markers for the progression of type 2 diabetes. J Cell Mol Med 2019;23:2753–68. https://doi.org/10.1111/jcmm.14182.Search in Google Scholar PubMed PubMed Central

9. Trabulus, S, Zor, MS, Turanli, ET, Dincer, T, Alagoz, S, Mese, M, et al.. FP507 Urinary exosomal miRNA levels reveal new potential biomarkers in type 2 diabetic nephropathy and FSGS. Nephrol Dial Transplant 2019;34:1–191. https://doi.org/10.1093/ndt/gfz106.fp507.Search in Google Scholar

10. Wang, G, Kwan, BCH, Lai, FMM, Chow, KM, Li, PKT, Szeto, CC. Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis. Am J Nephrol 2012;36:412–8. https://doi.org/10.1159/000343452.Search in Google Scholar PubMed

11. Ling, HY, Hu, B, Hu, XB, Zhong, J, Feng, SD, Qin, L, et al.. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes 2012;120:553–9. https://doi.org/10.1055/s-0032-1311644.Search in Google Scholar PubMed

12. McClelland, AD, Herman-Edelstein, M, Komers, R, Jha, JC, Winbanks, CE, Hagiwara, S, et al.. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci 2015;129:1237–49. https://doi.org/10.1042/cs20150427.Search in Google Scholar

13. Szeto, CC, Ching-Ha, KB, Ka-Bik, L, Mac-Moune, LF, Cheung-Lung, CP, Gang, W, et al.. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers 2012;33:137–44. https://doi.org/10.1155/2012/842764.Search in Google Scholar PubMed PubMed Central

14. Kato, M, Putta, S, Wang, M, Yuan, H, Lanting, L, Nair, I, et al.. TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009;11:881–9. https://doi.org/10.1038/ncb1897.Search in Google Scholar PubMed PubMed Central

15. Al-Kafaji, G, Al-Mahroos, G, Al-Muhtaresh, HA, Skrypnyk, C, Sabry, MA, Ramadan, AR. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: a potential blood-based biomarker. Exp Ther Med 2016;12:815–22. https://doi.org/10.3892/etm.2016.3395.Search in Google Scholar PubMed PubMed Central

16. Kato, M, Zhang, J, Wang, M, Lanting, L, Yuan, H, Rossi, JJ, et al.. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 2007;104:3432–7. https://doi.org/10.1073/pnas.0611192104.Search in Google Scholar PubMed PubMed Central

17. Krupa, A, Jenkins, R, Luo, DD, Lewis, A, Phillips, A, Fraser, D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010;21:438–47. https://doi.org/10.1681/asn.2009050530.Search in Google Scholar

18. Assmann, TS, Recamonde-Mendoza, M, Costa, AR, Puñales, M, Tschiedel, B, Canani, LH, et al.. Circulating miRNAs in diabetic kidney disease: case–control study and in silico analyses. Acta Diabetol 2019;56:55–65. https://doi.org/10.1007/s00592-018-1216-x.Search in Google Scholar PubMed

19. Assmann, TS, Recamonde-Mendoza, M, Puñales, M, Tschiedel, B, Canani, LH, Crispim, D. MicroRNA expression profile in plasma from type 1 diabetic patients: case-control study and bioinformatic analysis. Diabetes Res Clin Pract 2018;141:35–46. https://doi.org/10.1016/j.diabres.2018.03.044.Search in Google Scholar PubMed

20. Assmann, TS, Recamonde-Mendoza, M, De Souza, BM, Crispim, D. MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. Endocr Connect 2017;6:773–90. https://doi.org/10.1530/ec-17-0248.Search in Google Scholar

21. Assmann, TS, Recamonde-Mendoza, M, de Souza, BM, Bauer, AC, Crispim, D. MicroRNAs and diabetic kidney disease: systematic review and bioinformatic analysis. Mol Cell Endocrinol 2018;477:90–102. https://doi.org/10.1016/j.mce.2018.06.005.Search in Google Scholar PubMed

22. Delić, D, Eisele, C, Schmid, R, Baum, P, Wiech, F, Gerl, M, et al.. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLoS One 2016;11:1–16. https://doi.org/10.1371/journal.pone.0150154.Search in Google Scholar PubMed PubMed Central

23. American Diabetes Association. Standarts of medical care in diabetes-2014. Diabetes Care 2014;37:14–80.10.2337/dc14-S014Search in Google Scholar PubMed

24. Duttagupta, R, Jiang, R, Gollub, J, Getts, RC, Jones, KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011;6:1–14. https://doi.org/10.1371/journal.pone.0020769.Search in Google Scholar PubMed PubMed Central

25. Neal, CS, Michael, MZ, Pimlott, LK, Yong, TY, Li, JYZ, Gleadle, JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011;26:3794–802. https://doi.org/10.1093/ndt/gfr485.Search in Google Scholar PubMed

26. Yang, X, Liu, S, Zhang, R, Sun, B, Zhou, S, Chen, R, et al.. Microribonucleic acid-192 as a specific biomarker for the early diagnosis of diabetic kidney disease. J Diabetes Investig 2018;9:602–9. https://doi.org/10.1111/jdi.12753.Search in Google Scholar PubMed PubMed Central

27. Chien, HY, Chen, CY, Chiu, YH, Lin, YC, Li, WC. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci 2016;13:457–65. https://doi.org/10.7150/ijms.15548.Search in Google Scholar PubMed PubMed Central

28. Zampetaki, A, Kiechl, S, Drozdov, I, Willeit, P, Mayr, U, Prokopi, M, et al.. Plasma MicroRNA profiling reveals loss of endothelial MiR-126 and other MicroRNAs in type 2 diabetes. Circ Res 2010;107:810–7. https://doi.org/10.1161/circresaha.110.226357.Search in Google Scholar PubMed

29. Connolly, JH, Herriott, RM, Gupta, S. Ribonuclease in normal and uraemic human blood. Br J Exp Pathol 1962;43:402–8.Search in Google Scholar

30. Florijn, BW, Duijs, JMGJ, Levels, JH, Dallinga-Thie, GM, Wang, Y, Boing, AN, et al.. Diabetic nephropathy alters the distribution of circulating angiogenic MicroRNAs among extracellular vesicles, HDL, and Ago-2. Diabetes 2019;68:2287–300. https://doi.org/10.2337/db18-1360.Search in Google Scholar PubMed

31. Liu, F, Zhang, Z, Xin, G, Guo, L, Jiang, Q, Wang, Z. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1. Eur Rev Med Pharmacol Sci 2018;22:4252–60. https://doi.org/10.26355/eurrev_201807_15420.Search in Google Scholar PubMed

32. Fish, JE, Santoro, MM, Morton, SU, Yu, S, Wythe, JD, Bruneau, BG, et al.. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272–84. https://doi.org/10.1016/j.devcel.2008.07.008.Search in Google Scholar PubMed PubMed Central

33. Bijkerk, R, Duijs, JMGJ, Khairoun, M, Ter Horst, CJH, Van Der Pol, P, Mallat, MJ, et al.. Circulating MicroRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am J Transplant 2015;15:1081–90. https://doi.org/10.1111/ajt.13072.Search in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/dx-2022-0036).

Received: 2022-04-19
Accepted: 2022-07-23
Published Online: 2022-08-18

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Diagnostic and therapeutic approach to hypernatremia
  4. Opinion Papers
  5. The diagnostic potential and barriers of microbiome based therapeutics
  6. Pursuit of “endpoint diagnoses” as a cognitive forcing strategy to avoid premature diagnostic closure
  7. Guidelines and Recommendations
  8. The e-Autopsy/e-Biopsy: a systematic chart review to increase safety and diagnostic accuracy
  9. Original Articles
  10. Exploring procedure-based management reasoning: a case of tension pneumothorax
  11. A structured approach to EHR surveillance of diagnostic error in acute care: an exploratory analysis of two institutionally-defined case cohorts
  12. Human centered design workshops as a meta-solution to diagnostic disparities
  13. Longitudinal clinical reasoning theme embedded across four years of a medical school curriculum
  14. Using the Assessment of Reasoning Tool to facilitate feedback about diagnostic reasoning
  15. Evolution of throat symptoms during the COVID-19 pandemic in the US
  16. Evaluating the role of a fully automated SARS-CoV-2 antigen ECLIA immunoassay in the management of the SARS COV 2 pandemic on general population
  17. miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
  18. Letter to the Editors
  19. Convoluted molecular maze of neprilysin
  20. OPeNet: an AI-based platform implemented to facilitate clinical reasoning by primary care practitioners, as well as the virtuous co-management of chronic patients during and after the COVID-19 pandemic in Italy
  21. Letter to the Editor in reply to Diamandis “COVID-19 and the Le Chatelier’s principle”
https://doi.org/10.1515/dx-2022-0036
Keywords for this article
circulating microRNAs; diabetes mellitus; diabetic nephropathy

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Diagnostic and therapeutic approach to hypernatremia
  4. Opinion Papers
  5. The diagnostic potential and barriers of microbiome based therapeutics
  6. Pursuit of “endpoint diagnoses” as a cognitive forcing strategy to avoid premature diagnostic closure
  7. Guidelines and Recommendations
  8. The e-Autopsy/e-Biopsy: a systematic chart review to increase safety and diagnostic accuracy
  9. Original Articles
  10. Exploring procedure-based management reasoning: a case of tension pneumothorax
  11. A structured approach to EHR surveillance of diagnostic error in acute care: an exploratory analysis of two institutionally-defined case cohorts
  12. Human centered design workshops as a meta-solution to diagnostic disparities
  13. Longitudinal clinical reasoning theme embedded across four years of a medical school curriculum
  14. Using the Assessment of Reasoning Tool to facilitate feedback about diagnostic reasoning
  15. Evolution of throat symptoms during the COVID-19 pandemic in the US
  16. Evaluating the role of a fully automated SARS-CoV-2 antigen ECLIA immunoassay in the management of the SARS COV 2 pandemic on general population
  17. miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
  18. Letter to the Editors
  19. Convoluted molecular maze of neprilysin
  20. OPeNet: an AI-based platform implemented to facilitate clinical reasoning by primary care practitioners, as well as the virtuous co-management of chronic patients during and after the COVID-19 pandemic in Italy
  21. Letter to the Editor in reply to Diamandis “COVID-19 and the Le Chatelier’s principle”
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 27.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/dx-2022-0036/html
Scroll to top button